Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells

Journal of Endocrinological Investigation

Volumn 33, Issue 4, 2010, Pages 244-249

  Valenti, M T ^a   Giannini, S ^b   Donatelli, L ^a   Realdi, G ^b   Lo Cascio, V ^a   Dalle Carbonare, L ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Prostate cancer; RT real time PCR; STEAP; Z ledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; MESSENGER RNA; PROSTATE PROTEIN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; OXIDOREDUCTASE; STEAP1 PROTEIN, HUMAN; TUMOR ANTIGEN;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CASPASE 3; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 77953583239     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6622     Document Type: Article

References (20)

1. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has anti-myeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010, 126: 239-46.
2. Goffinet M, Thoulouzan M, Pradines A, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostate cells. BMC Cancer 2006, 6: 60.
3. Fromigue O, Kheddoumi N, Body JJ. Bisphosphonates antagonise bone growth factor's effects on human breast cancer cells survival. Br J Cancer 2003, 89: 178-84.
4. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13: 581-9.
5. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96: 133-8.
6. Samanna V, Ma T, Mak TW, Rogers M, Chellaiah MA. Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function. J Cell Physiol 2007, 213: 710-20.
7. Valenti MT, Dalle Carbonare L, Bertoldo F, Donatelli L, Lo Cascio V. The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells. Eur J Pharmacol 2008, 580: 36-42.
8. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999, 96: 14523-8.
9. Prevarskaya N, Skryma R, Bidaux G, Flourakis M, Shuba Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ 2007, 14: 1295-304.
10. Laniado ME, Lalani EN, Fraser SP, et al. Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 1997, 150: 1213-21.
11. Skryma RN, Prevarskaya NB, Dufy-Barbe L, Odessa MF, Audin J, Dufy B. Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate 1997, 33: 112-22.
12. Valenti MT, Dalle Carbonare L, Donatelli L, et al. STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett 2009, 273: 122-6.
13. Floras KV, Thomadaki H, Florou D, Talieri M, Scorilas A. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann N Y Acad Sci 2006, 1090: 89-97.
14. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003, 170: 246-52.
15. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996, 6: 986-94.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25: 402-8.
17. Levine EL, Renehan A, Gossiel R, et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995, 37: 1-9.
18. Sewing L, Steinberg F, Schmidt H, Göke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008, 13: 782-9.
19. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004, 11: 207-24.
20. Sanchez-Pulido L, Rojas AM, Valencia A, Martinez-A C, Andrade MA. ACRATA: a novel electron transfer domain associated to apoptosis and cancer. BMC Cancer 2004, 4: 98.